Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Sell
21
AKBA Quote, Financials, Valuation and Earnings
Last price:
$1.36
Seasonality move
:
-12.3%
Day range:
$1.34 - $1.41
52-week range:
$1.31 - $4.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.52x
P/B ratio:
8.68x
Volume:
2.8M
Avg. volume:
3M
1-year change:
-29.53%
Market cap:
$360.9M
Revenue:
$160.2M
EPS (TTM):
-$0.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
|
$56.2M | $0.02 | 3.47% | -95.21% | $5.40 |
|
AMGN
Amgen, Inc.
|
$9.5B | $4.77 | 6.99% | 59.8% | $331.59 |
|
OGN
Organon & Co.
|
$1.5B | $0.74 | -4.4% | 76.57% | $9.36 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 2.06% | 43.22% | $28.66 |
|
TBPH
Theravance Biopharma, Inc.
|
$43M | -$0.05 | 129.3% | -80.69% | $26.71 |
|
ZVRA
Zevra Therapeutics, Inc.
|
$28.1M | $0.05 | 132.94% | -99.63% | $22.54 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
|
$1.36 | $5.40 | $360.9M | -- | $0.00 | 0% | 1.52x |
|
AMGN
Amgen, Inc.
|
$330.41 | $331.59 | $177.9B | 25.54x | $2.38 | 2.88% | 4.99x |
|
OGN
Organon & Co.
|
$8.76 | $9.36 | $2.3B | 4.55x | $0.02 | 3.88% | 0.36x |
|
PFE
Pfizer Inc.
|
$25.65 | $28.66 | $145.8B | 14.95x | $0.43 | 6.71% | 2.33x |
|
TBPH
Theravance Biopharma, Inc.
|
$20.01 | $26.71 | $1B | 35.57x | $0.00 | 0% | 12.56x |
|
ZVRA
Zevra Therapeutics, Inc.
|
$8.93 | $22.54 | $502.7M | 14.16x | $0.00 | 0% | 5.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
|
83.68% | 1.509 | 29.46% | 1.76x |
|
AMGN
Amgen, Inc.
|
85.02% | -0.224 | 35.92% | 0.82x |
|
OGN
Organon & Co.
|
90.69% | -0.836 | 317.94% | 0.81x |
|
PFE
Pfizer Inc.
|
39.94% | 0.405 | 42.51% | 0.81x |
|
TBPH
Theravance Biopharma, Inc.
|
16.08% | 0.446 | 6.03% | 9.30x |
|
ZVRA
Zevra Therapeutics, Inc.
|
32.02% | 1.514 | 11.73% | 8.25x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AKBA
Akebia Therapeutics, Inc.
|
$49.1M | $4.4M | -7.86% | -- | 7.57% | $28M |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
OGN
Organon & Co.
|
$857M | $358M | 5.26% | 79.63% | 22.35% | $149M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
TBPH
Theravance Biopharma, Inc.
|
$18.6M | -$6.5M | 11.74% | 14.9% | -32.29% | -$6.5M |
|
ZVRA
Zevra Therapeutics, Inc.
|
$24.5M | $4.1M | 24.95% | 44.06% | 15.9% | $4.2M |
Akebia Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns AKBA or AMGN?
Amgen, Inc. has a net margin of 0.92% compared to Akebia Therapeutics, Inc.'s net margin of 33.55%. Akebia Therapeutics, Inc.'s return on equity of -- beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.83.49% $0.00 $254.9M AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About AKBA or AMGN?
Akebia Therapeutics, Inc. has a consensus price target of $5.40, signalling upside risk potential of 297.06%. On the other hand Amgen, Inc. has an analysts' consensus of $331.59 which suggests that it could grow by 0.36%. Given that Akebia Therapeutics, Inc. has higher upside potential than Amgen, Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 AMGNAmgen, Inc.11 14 2 -
Is AKBA or AMGN More Risky?
Akebia Therapeutics, Inc. has a beta of 0.354, which suggesting that the stock is 64.559% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.454, suggesting its less volatile than the S&P 500 by 54.551%.
-
Which is a Better Dividend Stock AKBA or AMGN?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.88% to investors and pays a quarterly dividend of $2.38 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or AMGN?
Akebia Therapeutics, Inc. quarterly revenues are $58.8M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Akebia Therapeutics, Inc.'s net income of $540K is lower than Amgen, Inc.'s net income of $3.2B. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while Amgen, Inc.'s PE ratio is 25.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.52x versus 4.99x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.52x -- $58.8M $540K AMGNAmgen, Inc.4.99x 25.54x $9.6B $3.2B
-
Which has Higher Returns AKBA or OGN?
Organon & Co. has a net margin of 0.92% compared to Akebia Therapeutics, Inc.'s net margin of 9.99%. Akebia Therapeutics, Inc.'s return on equity of -- beat Organon & Co.'s return on equity of 79.63%.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.83.49% $0.00 $254.9M OGNOrganon & Co.53.5% $0.61 $9.7B -
What do Analysts Say About AKBA or OGN?
Akebia Therapeutics, Inc. has a consensus price target of $5.40, signalling upside risk potential of 297.06%. On the other hand Organon & Co. has an analysts' consensus of $9.36 which suggests that it could grow by 6.82%. Given that Akebia Therapeutics, Inc. has higher upside potential than Organon & Co., analysts believe Akebia Therapeutics, Inc. is more attractive than Organon & Co..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 OGNOrganon & Co.0 3 0 -
Is AKBA or OGN More Risky?
Akebia Therapeutics, Inc. has a beta of 0.354, which suggesting that the stock is 64.559% less volatile than S&P 500. In comparison Organon & Co. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AKBA or OGN?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Organon & Co. offers a yield of 3.88% to investors and pays a quarterly dividend of $0.02 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. Organon & Co. pays out 33.59% of its earnings as a dividend. Organon & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AKBA or OGN?
Akebia Therapeutics, Inc. quarterly revenues are $58.8M, which are smaller than Organon & Co. quarterly revenues of $1.6B. Akebia Therapeutics, Inc.'s net income of $540K is lower than Organon & Co.'s net income of $160M. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while Organon & Co.'s PE ratio is 4.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.52x versus 0.36x for Organon & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.52x -- $58.8M $540K OGNOrganon & Co.0.36x 4.55x $1.6B $160M
-
Which has Higher Returns AKBA or PFE?
Pfizer Inc. has a net margin of 0.92% compared to Akebia Therapeutics, Inc.'s net margin of 21.32%. Akebia Therapeutics, Inc.'s return on equity of -- beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.83.49% $0.00 $254.9M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About AKBA or PFE?
Akebia Therapeutics, Inc. has a consensus price target of $5.40, signalling upside risk potential of 297.06%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 11.72%. Given that Akebia Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 PFEPfizer Inc.7 15 1 -
Is AKBA or PFE More Risky?
Akebia Therapeutics, Inc. has a beta of 0.354, which suggesting that the stock is 64.559% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.
-
Which is a Better Dividend Stock AKBA or PFE?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.71% to investors and pays a quarterly dividend of $0.43 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or PFE?
Akebia Therapeutics, Inc. quarterly revenues are $58.8M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Akebia Therapeutics, Inc.'s net income of $540K is lower than Pfizer Inc.'s net income of $3.6B. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.52x versus 2.33x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.52x -- $58.8M $540K PFEPfizer Inc.2.33x 14.95x $16.7B $3.6B
-
Which has Higher Returns AKBA or TBPH?
Theravance Biopharma, Inc. has a net margin of 0.92% compared to Akebia Therapeutics, Inc.'s net margin of 18.08%. Akebia Therapeutics, Inc.'s return on equity of -- beat Theravance Biopharma, Inc.'s return on equity of 14.9%.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.83.49% $0.00 $254.9M TBPHTheravance Biopharma, Inc.92.96% $0.07 $277.3M -
What do Analysts Say About AKBA or TBPH?
Akebia Therapeutics, Inc. has a consensus price target of $5.40, signalling upside risk potential of 297.06%. On the other hand Theravance Biopharma, Inc. has an analysts' consensus of $26.71 which suggests that it could grow by 33.51%. Given that Akebia Therapeutics, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Theravance Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 TBPHTheravance Biopharma, Inc.5 2 0 -
Is AKBA or TBPH More Risky?
Akebia Therapeutics, Inc. has a beta of 0.354, which suggesting that the stock is 64.559% less volatile than S&P 500. In comparison Theravance Biopharma, Inc. has a beta of 0.139, suggesting its less volatile than the S&P 500 by 86.12%.
-
Which is a Better Dividend Stock AKBA or TBPH?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theravance Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. Theravance Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or TBPH?
Akebia Therapeutics, Inc. quarterly revenues are $58.8M, which are larger than Theravance Biopharma, Inc. quarterly revenues of $20M. Akebia Therapeutics, Inc.'s net income of $540K is lower than Theravance Biopharma, Inc.'s net income of $3.6M. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while Theravance Biopharma, Inc.'s PE ratio is 35.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.52x versus 12.56x for Theravance Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.52x -- $58.8M $540K TBPHTheravance Biopharma, Inc.12.56x 35.57x $20M $3.6M
-
Which has Higher Returns AKBA or ZVRA?
Zevra Therapeutics, Inc. has a net margin of 0.92% compared to Akebia Therapeutics, Inc.'s net margin of -2.09%. Akebia Therapeutics, Inc.'s return on equity of -- beat Zevra Therapeutics, Inc.'s return on equity of 44.06%.
Company Gross Margin Earnings Per Share Invested Capital AKBAAkebia Therapeutics, Inc.83.49% $0.00 $254.9M ZVRAZevra Therapeutics, Inc.94.04% -$0.01 $195.9M -
What do Analysts Say About AKBA or ZVRA?
Akebia Therapeutics, Inc. has a consensus price target of $5.40, signalling upside risk potential of 297.06%. On the other hand Zevra Therapeutics, Inc. has an analysts' consensus of $22.54 which suggests that it could grow by 152.45%. Given that Akebia Therapeutics, Inc. has higher upside potential than Zevra Therapeutics, Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Zevra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AKBAAkebia Therapeutics, Inc.4 0 0 ZVRAZevra Therapeutics, Inc.6 0 0 -
Is AKBA or ZVRA More Risky?
Akebia Therapeutics, Inc. has a beta of 0.354, which suggesting that the stock is 64.559% less volatile than S&P 500. In comparison Zevra Therapeutics, Inc. has a beta of 1.080, suggesting its more volatile than the S&P 500 by 8.038%.
-
Which is a Better Dividend Stock AKBA or ZVRA?
Akebia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics, Inc. pays -- of its earnings as a dividend. Zevra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKBA or ZVRA?
Akebia Therapeutics, Inc. quarterly revenues are $58.8M, which are larger than Zevra Therapeutics, Inc. quarterly revenues of $26.1M. Akebia Therapeutics, Inc.'s net income of $540K is higher than Zevra Therapeutics, Inc.'s net income of -$544K. Notably, Akebia Therapeutics, Inc.'s price-to-earnings ratio is -- while Zevra Therapeutics, Inc.'s PE ratio is 14.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics, Inc. is 1.52x versus 5.78x for Zevra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKBAAkebia Therapeutics, Inc.1.52x -- $58.8M $540K ZVRAZevra Therapeutics, Inc.5.78x 14.16x $26.1M -$544K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
75
AGX alert for Jan 17
Argan, Inc. [AGX] is up 16.4% over the past day.
Buy
80
ASTS alert for Jan 17
AST Spacemobile, Inc. [ASTS] is up 14.32% over the past day.
Buy
84
IREN alert for Jan 17
IREN Ltd. [IREN] is up 11.35% over the past day.
